---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-044128"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2021-08-13T23:59:59+00:00"
generated_at: "2026-06-29T11:32:53.225631+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q2 2021 net loss $24.5M; cash $339M; PC14586 trial enrollment ongoing

## Summary
- Net loss for H1 2021 was $24.5M vs $15.2M in H1 2020.
- Cash, cash equivalents & marketable securities $339.0M at June 30, 2021.
- R&D expenses $15.2M (H1 2021) vs $11.8M (H1 2020) on PC14586 development.
- Continued enrollment in Phase 1/2 trial of p53 Y220C reactivator PC14586.
- Activated 12 clinical trial sites across leading US oncology centers.

## SEC filing metadata
- accession: 0001564590-21-044128
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2021-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000156459021044128/0001564590-21-044128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000156459021044128/pmvp-8k_20210813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-044128
- JSON: https://secwatch.observer/filing/0001564590-21-044128.json
- Plain text: https://secwatch.observer/filing/0001564590-21-044128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.